GEN-MKT-18-7897-A
Aug 14, 2024 | Blogs, Pharma, ZenoTOF 7600 system | 0 comments
Read Time: 2 minutes
Targeted protein degraders (TPD) are a relatively new therapeutic modality that opens the potential to target disease-causing proteins. These disease-causing proteins have been highly challenging for traditional small-molecule therapeutics to treat, making TPDs an exciting new therapeutic modality.
We are still developing our knowledge about TPDs and their behavior and optimizing analytical protocols to characterize and monitor them within the drug development process.
TPDs are typically dosed at low levels which makes their analysis in complex biological matrices challenging. Bioanalytical scientists who work with TPD compounds are striving to develop sensitive assays that reliably detect nanomolar concentrations of these highly potent drug candidates.
Learn more here > Targeted protein degraders and PROTACs (sciex.com)
Metabolite identification (MetID) is a critical step in drug development due to its impact on drug efficacy and safety. LC-MS platforms provide good selectivity and sensitivity making it the preferred technique for MetID. Traditionally, LC-MS experiments have used collision-induced dissociation (CID) to fragment and identify the metabolites. With some metabolites, the fragment ions generated by CID do not always generate a conclusive result leading to alternative techniques being needed to meet the regulatory requirements. Deploying electron-activated dissociation (EAD) can help in these circumstances.
In this webinar, An approach to streamline and simplify the identification of crucial metabolites from targeted protein degraders, Ebru Selen explains how EAD can be used for MetID analysis, allowing scientists to:
Metabolite identification workflow
Electron-activated dissociation (EAD) is a fragmentation technique available on the ZenoTOF 7600 system that causes ions in an LC-MS/MS experiment to fragment in locations that differ from where they fragment with CID, providing additional information to scientists. For metabolite identification, this could mean confident localization of the site of metabolism, removing the need for further safety testing.
Join our email list for pharma news from SCIEX: Request information (sciex.com)
Waterproof jackets. Stain-resistant shoes. Easy-clean fabrics are marketed as “performance.” Behind those everyday claims sits a class of chemicals now reshaping regulation, brand accountability, and laboratory science: PFAS.
For decades, SCIEX has been part of bioanalytical innovation, empowering scientists in pharma and biopharma to push the boundaries of sensitivity, accuracy, and throughput. Across complex workflows and increasingly challenging therapeutic modalities.
Trifluoroacetic acid (TFA) is emerging as one of the most concerning ultrashort-chain PFAS in Europe’s food supply – particularly in cereals, a staple consumed daily by millions. A report from PAN Europe reveals a widespread and largely unmonitored contamination trend that raises serious questions about food safety, regulatory blind spots, and future monitoring strategies.
Posted by
You must be logged in to post a comment.
Share this post with your network